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Abstract
IMPORTANCE—Definitions of sepsis and septic shock were last revised in 2001. Considerable 
advances have since been made into the pathobiology (changes in organ function, morphology, cell 
biology, biochemistry, immunology, and circulation), management, and epidemiology of sepsis, 
suggesting the need for reexamination.
OBJECTIVE—To evaluate and, as needed, update definitions for sepsis and septic shock.
PROCESS—A task force (n = 19) with expertise in sepsis pathobiology, clinical trials, and 
epidemiology was convened by the Society of Critical Care Medicine and the European Society of 
Intensive Care Medicine. Definitions and clinical criteria were generated through meetings, Delphi 
processes, analysis of electronic health record databases, and voting, followed by circulation to 
international professional societies, requesting peer review and endorsement (by 31 societies listed 
in the Acknowledgment).
KEY FINDINGS FROMEVIDENCE SYNTHESIS—Limitations of previous definitions 
included an excessive focus on inflammation, the misleading model that sepsis follows a 
continuum through severe sepsis to shock, and inadequate specificity and sensitivity of the 
systemic inflammatory response syndrome (SIRS) criteria. Multiple definitions and terminologies 
are currently in use for sepsis, septic shock, and organ dysfunction, leading to discrepancies in 
reported incidence and observed mortality. The task force concluded the term severe sepsis was 
redundant.
RECOMMENDATIONS—Sepsis should be defined as life-threatening organ dysfunction caused 
by a dysregulated host response to infection. For clinical operationalization, organ dysfunction can 
be represented by an increase in the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) 
score of 2 points or more, which is associated with an in-hospital mortality greater than 10%. 
Septic shock should be defined as a subset of sepsis in which particularly profound circulatory, 
cellular, and metabolic abnormalities are associated with a greater risk of mortality than with 
sepsis alone. Patients with septic shock can be clinically identified by a vasopressor requirement to 
maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 
mmol/L (>18 mg/dL) in the absence of hypovolemia. This combination is associated with hospital 
mortality rates greater than 40%. In out-of-hospital, emergency department, or general hospital 
ward settings, adult patients with suspected infection can be rapidly identified as being more likely 
to have poor outcomes typical of sepsis if they have at least 2 of the following clinical criteria that 
together constitute a new bedside clinical score termed quickSOFA (qSOFA): respiratory rate of 
22/min or greater, altered mentation, or systolic blood pressure of 100 mm Hg or less.
CONCLUSIONS AND RELEVANCE—These updated definitions and clinical criteria should 
replace previous definitions, offer greater consistency for epidemiologic studies and clinical trials, 
and facilitate earlier recognition and more timely management of patients with sepsis or at risk of 
developing sepsis.
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Sepsis, a syndrome of physiologic, pathologic, and biochemical abnormalities induced by 
infection, is a major public health concern, accounting for more than $20 billion (5.2%) of 
total US hospital costs in 2011.1 The reported incidence of sepsis is increasing,2,3 likely 
reflecting aging populations with more comorbidities, greater recognition,4 and, in some 
countries, reimbursement-favorable coding.5 Although the true incidence is unknown, 
conservative estimates indicate that sepsis is a leading cause of mortality and critical illness 
worldwide.6,7 Furthermore, there is increasing awareness that patients who survive sepsis 
often have long-term physical, psychological, and cognitive disabilities with significant 
health care and social implications.8
A 1991 consensus conference9 developed initial definitions that focused on the then-
prevailing view that sepsis resulted from a host’s systemic inflammatory response syndrome 
(SIRS) to infection (Box 1). Sepsis complicated by organ dysfunction was termed severe 
sepsis, which could progress to septic shock, defined as “sepsis-induced hypotension 
persisting despite adequate fluid resuscitation.” A 2001 task force, recognizing limitations 
with these definitions, expanded the list of diagnostic criteria but did not offer alternatives 
because of the lack of supporting evidence.10 In effect, the definitions of sepsis, septic 
shock, and organ dysfunction have remained largely unchanged for more than 2 decades.
The Process of Developing New Definitions
Recognizing the need to reexamine the current definitions,11 the European Society of 
Intensive Care Medicine and the Society of Critical Care Medicine convened a task force of 
19 critical care, infectious disease, surgical, and pulmonary specialists in January 2014. 
Unrestricted funding support was provided by the societies, and the task force retained 
complete autonomy. The societies each nominated cochairs (Drs Deutschman and Singer), 
who selected members according to their scientific expertise in sepsis epidemiology, clinical 
trials, and basic or translational research.
The group engaged in iterative discussions via 4 face-to-face meetings between January 
2014 and January 2015, email correspondence, and voting. Existing definitions were 
revisited in light of an enhanced appreciation of the pathobiology and the availability of 
large electronic health record databases and patient cohorts.
An expert consensus process, based on a current understanding of sepsis-induced changes in 
organ function, morphology, cell biology, biochemistry, immunology, and circulation 
(collectively referred to as pathobiology), forged agreement on updated definition(s) and the 
criteria to be tested in the clinical arena (content validity). The distinction between 
definitions and clinical criteria is discussed below. The agreement between potential clinical 
criteria (construct validity) and the ability of the criteria to predict outcomes typical of 
sepsis, such as need for intensive care unit (ICU) admission or death (predictive validity, a 
form of criterion validity), were then tested. These explorations were performed in multiple 
large electronic health record databases that also addressed the absence (missingness) of 
individual elements of different organ dysfunction scores and the question of generalizability 
(ecologic validity).12 A systematic literature review and Delphi consensus methods were 
also used for the definition and clinical criteria describing septic shock.13
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When compiled, the task force recommendations with supporting evidence, including 
original research, were circulated to major international societies and other relevant bodies 
for peer review and endorsement (31 endorsing societies are listed at the end of this article).
Issues Addressed by the Task Force
The task force sought to differentiate sepsis from uncomplicated infection and to update 
definitions of sepsis and septic shock to be consistent with improved understanding of the 
pathobiology. A definition is the description of an illness concept; thus, a definition of sepsis 
should describe what sepsis “is.” This chosen approach allowed discussion of biological 
concepts that are currently incompletely understood, such as genetic influences and cellular 
abnormalities. The sepsis illness concept is predicated on infection as its trigger, 
acknowledging the current challenges in the microbiological identification of infection. It 
was not, however, within the task force brief to examine definitions of infection.
The task force recognized that sepsis is a syndrome without, at present, a validated criterion 
standard diagnostic test. There is currently no process to operationalize the definitions of 
sepsis and septic shock, a key deficit that has led to major variations in reported incidence 
and mortality rates (see later discussion). The task force determined that there was an 
important need for features that can be identified and measured in individual patients and 
sought to provide such criteria to offer uniformity. Ideally, these clinical criteria should 
identify all the elements of sepsis (infection, host response, and organ dysfunction), be 
simple to obtain, and be available promptly and at a reasonable cost or burden. Furthermore, 
it should be possible to test the validity of these criteria with available large clinical data sets 
and, ultimately, prospectively. In addition, clinical criteria should be available to provide 
practitioners in out-of-hospital, emergency department, and hospital ward settings with the 
capacity to better identify patients with suspected infection likely to progress to a life-
threatening state. Such early recognition is particularly important because prompt 
management of septic patients may improve outcomes.4
In addition, to provide a more consistent and reproducible picture of sepsis incidence and 
outcomes, the task force sought to integrate the biology and clinical identification of sepsis 
with its epidemiology and coding.
Identified Challenges and Opportunities
Assessing the Validity of Definitions When There Is No Gold Standard
Sepsis is not a specific illness but rather a syndrome encompassing a still-uncertain 
pathobiology. At present, it can be identified by a constellation of clinical signs and 
symptoms in a patient with suspected infection. Because no gold standard diagnostic test 
exists, the task force sought definitions and supporting clinical criteria that were clear and 
fulfilled multiple domains of usefulness and validity.
Improved Understanding of Sepsis Pathobiology
Sepsis is a multifaceted host response to an infecting pathogen that may be significantly 
amplified by endogenous factors.14,15 The original conceptualization of sepsis as infection 
Singer et al. Page 4
JAMA. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
with at least 2 of the 4 SIRS criteria focused solely on inflammatory excess. However, the 
validity of SIRS as a descriptor of sepsis pathobiology has been challenged. Sepsis is now 
recognized to involve early activation of both pro- and anti-inflammatory responses,16 along 
with major modifications in nonimmunologic pathways such as cardiovascular, neuronal, 
autonomic, hormonal, bioenergetic, metabolic, and coagulation,14,17,18 all of which have 
prognostic significance. Organ dysfunction, even when severe, is not associated with 
substantial cell death.19
The broader perspective also emphasizes the significant biological and clinical heterogeneity 
in affected individuals,20 with age, underlying comorbidities, concurrent injuries (including 
surgery) and medications, and source of infection adding further complexity.21 This diversity 
cannot be appropriately recapitulated in either animal models or computer simulations.14 
With further validation, multichannel molecular signatures (eg, transcriptomic, metabolomic, 
proteomic) will likely lead to better characterization of specific population subsets.22,23 
Such signatures may also help to differentiate sepsis from noninfectious insults such as 
trauma or pancreatitis, in which a similar biological and clinical host response may be 
triggered by endogenous factors.24 Key concepts of sepsis describing its protean nature are 
highlighted in Box 2.
Variable Definitions
A better understanding of the underlying pathobiology has been accompanied by the 
recognition that many existing terms (eg, sepsis, severe sepsis) are used interchangeably, 
whereas others are redundant (eg, sepsis syndrome) or overly narrow (eg, septicemia). 
Inconsistent strategies in selecting International Classification of Diseases, Ninth Revision 
(ICD-9), and ICD-10 codes have compounded the problem.
Sepsis—The current use of 2 or more SIRS criteria (Box 1) to identify sepsis was 
unanimously considered by the task force to be unhelpful. Changes in white blood cell 
count, temperature, and heart rate reflect inflammation, the host response to “danger” in the 
form of infection or other insults. The SIRS criteria do not necessarily indicate a 
dysregulated, life-threatening response. SIRS criteria are present in many hospitalized 
patients, including those who never develop infection and never incur adverse outcomes 
(poor discriminant validity).25 In addition, 1 in 8 patients admitted to critical care units in 
Australia and New Zealand with infection and new organ failure did not have the requisite 
minimum of 2 SIRS criteria to fulfill the definition of sepsis (poor concurrent validity) yet 
had protracted courses with significant morbidity and mortality.26 Discriminant validity and 
convergent validity constitute the 2 domains of construct validity; the SIRS criteria thus 
perform poorly on both counts.
Organ Dysfunction or Failure—Severity of organ dysfunction has been assessed with 
various scoring systems that quantify abnormalities according to clinical findings, laboratory 
data, or therapeutic interventions. Differences in these scoring systems have also led to 
inconsistency in reporting. The predominant score in current use is the Sequential Organ 
Failure Assessment (SOFA) (originally the Sepsis-related Organ Failure Assessment27) 
(Table 1).28 A higher SOFA score is associated with an increased probability of mortality.28 
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The score grades abnormality by organ system and accounts for clinical interventions. 
However, laboratory variables, namely, PaO2, platelet count, creatinine level, and bilirubin 
level, are needed for full computation. Furthermore, selection of variables and cutoff values 
were developed by consensus, and SOFA is not well known outside the critical care 
community. Other organ failure scoring systems exist, including systems built from 
statistical models, but none are in common use.
Septic Shock—Multiple definitions for septic shock are currently in use. Further details 
are provided in an accompanying article by Shankar-Hari et al.13 A systematic review of the 
operationalization of current definitions highlights significant heterogeneity in reported 
mortality. This heterogeneity resulted from differences in the clinical variables chosen 
(varying cutoffs for systolic or mean blood pressure ± diverse levels of hyperlactatemia ± 
vasopressor use ± concurrent new organ dysfunction ± defined fluid resuscitation volume/
targets), the data source and coding methods, and enrollment dates.
A Need for Sepsis Definitions for the Public and for Health Care 
Practitioners
Despite its worldwide importance,6,7 public awareness of sepsis is poor.29 Furthermore, the 
various manifestations of sepsis make diagnosis difficult, even for experienced clinicians. 
Thus, the public needs an understandable definition of sepsis, whereas health care 
practitioners require improved clinical prompts and diagnostic approaches to facilitate 
earlier identification and an accurate quantification of the burden of sepsis.
Results/Recommendations
Definition of Sepsis
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host 
response to infection (Box 3). This new definition emphasizes the primacy of the 
nonhomeostatic host response to infection, the potential lethality that is considerably in 
excess of a straightforward infection, and the need for urgent recognition. As described later, 
even a modest degree of organ dysfunction when infection is first suspected is associated 
with an in-hospital mortality in excess of 10%. Recognition of this condition thus merits a 
prompt and appropriate response.
Nonspecific SIRS criteria such as pyrexia or neutrophilia will continue to aid in the general 
diagnosis of infection. These findings complement features of specific infections (eg, rash, 
lung consolidation, dysuria, peritonitis) that focus attention toward the likely anatomical 
source and infecting organism. However, SIRS may simply reflect an appropriate host 
response that is frequently adaptive. Sepsis involves organ dysfunction, indicating a 
pathobiology more complex than infection plus an accompanying inflammatory response 
alone. The task force emphasis on life-threatening organ dysfunction is consistent with the 
view that cellular defects underlie physiologic and biochemical abnormalities within specific 
organ systems. Under this terminology, “severe sepsis”becomes superfluous. Sepsis should 
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generally warrant greater levels of monitoring and intervention, including possible 
admission to critical care or high-dependency facilities.
Clinical Criteria to Identify Patients With Sepsis
The task force recognized that no current clinical measures reflect the concept of a 
dysregulated host response. However, as noted by the 2001 task force, many bedside 
examination findings and routine laboratory test results are indicative of inflammation or 
organ dysfunction.10 The task force therefore evaluated which clinical criteria best identified 
infected patients most likely to have sepsis. This objective was achieved by interrogating 
large data sets of hospitalized patients with presumed infection, assessing agreement among 
existing scores of inflammation (SIRS)9 or organ dysfunction (eg, SOFA,27,28 Logistic 
Organ Dysfunction System30) (construct validity), and delineating their correlation with 
subsequent outcomes (predictive validity). In addition, multivariable regression was used to 
explore the performance of 21 bedside and laboratory criteria proposed by the 2001 task 
force.10
Full details are found in the accompanying article by Seymour et al.12 In brief, electronic 
health record data of 1.3 million encounters at 12 community and academic hospitals within 
the University of Pittsburgh Medical Center health system in southwestern Pennsylvania 
were studied. There were 148 907 patients with suspected infection, identified as those who 
had body fluids sampled for culture and received antibiotics. Two outcomes—hospital 
mortality and mortality, ICU stay of 3 days or longer, or both—were used to assess 
predictive validity both overall and across deciles of baseline risk as determined by age, sex, 
and comorbidity. For infected patients both inside and outside of the ICU, predictive validity 
was determined with 2 metrics for each criterion: the area under the receiver operating 
characteristic curve (AUROC) and the change in outcomes comparing patients with a score 
of either 2 points or more or fewer than 2 points in the different scoring systems9,27,30 across 
deciles of baseline risk. These criteria were also analyzed in 4 external US and non-US data 
sets containing data from more than 700 000 patients (cared for in both community and 
tertiary care facilities) with both community- and hospital-acquired infection.
In ICU patients with suspected infection in the University of Pittsburgh Medical Center data 
set, discrimination for hospital mortality with SOFA (AUROC = 0.74; 95% CI, 0.73–0.76) 
and the Logistic Organ Dysfunction System (AUROC = 0.75; 95% CI, 0.72–0.76) was 
superior to that with SIRS (AUROC = 0.64; 95% CI, 0.62–0.66). The predictive validity of a 
change in SOFA score of 2 or greater was similar (AUROC = 0.72; 95% CI, 0.70–0.73). For 
patients outside the ICU and with suspected infection, discrimination of hospital mortality 
with SOFA (AUROC = 0.79; 95% CI, 0.78–0.80) or change in SOFA score (AUROC = 0.79; 
95% CI, 0.78–0.79) was similar to that with SIRS (AUROC = 0.76; 95% CI, 0.75–0.77).
Because SOFA is better known and simpler than the Logistic Organ Dysfunction System, 
the task force recommends using a change in baseline of the total SOFA score of 2 points or 
more to represent organ dysfunction (Box 3). The baseline SOFA score should be assumed 
to be zero unless the patient is known to have preexisting (acute or chronic) organ 
dysfunction before the onset of infection. Patients with a SOFA score of 2 or more had an 
overall mortality risk of approximately 10% in a general hospital population with presumed 
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infection.12 This is greater than the overall mortality rate of 8.1% for ST-segment elevation 
myocardial infarction,31 a condition widely held to be life threatening by the community and 
by clinicians. Depending on a patient’s baseline level of risk, a SOFA score of 2 or greater 
identified a 2- to 25-fold increased risk of dying compared with patients with a SOFA score 
less than 2.12
As discussed later, the SOFA score is not intended to be used as a tool for patient 
management but as a means to clinically characterize a septic patient. Components of SOFA 
(such as creatinine or bilirubin level) require laboratory testing and thus may not promptly 
capture dysfunction in individual organ systems. Other elements, such as the cardiovascular 
score, can be affected by iatrogenic interventions. However, SOFA has widespread 
familiarity within the critical care community and a well-validated relationship to mortality 
risk. It can be scored retrospectively, either manually or by automated systems, from clinical 
and laboratory measures often performed routinely as part of acute patient management. The 
task force noted that there are a number of novel biomarkers that can identify renal and 
hepatic dysfunction or coagulopathy earlier than the elements used in SOFA, but these 
require broader validation before they can be incorporated into the clinical criteria 
describing sepsis. Future iterations of the sepsis definitions should include an updated SOFA 
score with more optimal variable selection, cutoff values, and weighting, or a superior 
scoring system.
Screening for Patients Likely to Have Sepsis
A parsimonious clinical model developed with multivariable logistic regression identified 
that any 2 of 3 clinical variables—Glasgow Coma Scale score of 13 or less, systolic blood 
pressure of 100 mm Hg or less, and respiratory rate 22/min or greater—offered predictive 
validity (AUROC = 0.81; 95% CI, 0.80–0.82) similar to that of the full SOFA score outside 
the ICU.12 This model was robust to multiple sensitivity analyses including a more simple 
assessment of altered mentation (Glasgow Coma Scale score <15) and in the out-of-hospital, 
emergency department, and ward settings within the external US and non-US data sets.
For patients with suspected infection within the ICU, the SOFA score had predictive validity 
(AUROC = 0.74; 95% CI, 0.73–0.76) superior to that of this model (AUROC = 0.66; 95% 
CI, 0.64–0.68), likely reflecting the modifying effects of interventions (eg, vasopressors, 
sedative agents, mechanical ventilation). Addition of lactate measurement did not 
meaningfully improve predictive validity but may help identify patients at intermediate risk.
This new measure, termed qSOFA (for quick SOFA) and incorporating altered mentation, 
systolic blood pressure of 100 mm Hg or less, and respiratory rate of 22/min or greater, 
provides simple bedside criteria to identify adult patients with suspected infection who are 
likely to have poor outcomes (Box 4). Because predictive validity was unchanged (P = .55), 
the task force chose to emphasize altered mentation because it represents any Glasgow 
Coma Scale score less than 15 and will reduce the measurement burden. Although qSOFA is 
less robust than a SOFA score of 2 or greater in the ICU, it does not require laboratory tests 
and can be assessed quickly and repeatedly. The task force suggests that qSOFA criteria be 
used to prompt clinicians to further investigate for organ dysfunction, to initiate or escalate 
therapy as appropriate, and to consider referral to critical care or increase the frequency of 
Singer et al. Page 8
JAMA. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
monitoring, if such actions have not already been undertaken. The task force considered that 
positive qSOFA criteria should also prompt consideration of possible infection in patients 
not previously recognized as infected.
Definition of Septic Shock
Septic shock is defined as a subset of sepsis in which underlying circulatory and cellular 
metabolism abnormalities are profound enough to substantially increase mortality (Box 3). 
The 2001 task force definitions described septic shock as “a state of acute circulatory 
failure.”10 The task force favored a broader view to differentiate septic shock from 
cardiovascular dysfunction alone and to recognize the importance of cellular abnormalities 
(Box 3). There was unanimous agreement that septic shock should reflect a more severe 
illness with a much higher likelihood of death than sepsis alone.
Clinical Criteria to Identify Septic Shock
Further details are provided in the accompanying article by Shankar-Hari et al.13 First, a 
systematic review assessed how current definitions were operationalized. This informed a 
Delphi process conducted among the task force members to determine the updated septic 
shock definition and clinical criteria. This process was iterative and informed by 
interrogation of databases, as summarized below.
The Delphi process assessed agreements on descriptions of terms such as “hypotension,” 
“need for vasopressor therapy,” “raised lactate,” and “adequate fluid resuscitation” for 
inclusion within the new clinical criteria. The majority (n = 14/17; 82.4%) of task force 
members voting on this agreed that hypotension should be denoted as a mean arterial 
pressure less than 65mmHg according to the pragmatic decision that this was most often 
recorded in data sets derived from patients with sepsis. Systolic blood pressure was used as a 
qSOFA criterion because it was most widely recorded in the electronic health record data 
sets.
A majority (11/17; 64.7%) of the task force agreed, whereas 2 (11.8%) disagreed, that an 
elevated lactate level is reflective of cellular dysfunction in sepsis, albeit recognizing that 
multiple factors, such as insufficient tissue oxygen delivery, impaired aerobic respiration, 
accelerated aerobic glycolysis, and reduced hepatic clearance, also contribute.32 
Hyperlactatemia is, however, a reasonable marker of illness severity, with higher levels 
predictive of higher mortality.33 Criteria for “adequate fluid resuscitation” or “need for 
vasopressor therapy” could not be explicitly specified because these are highly user 
dependent, relying on variable monitoring modalities and hemodynamic targets for 
treatment.34 Other aspects of management, such as sedation and volume status assessment, 
are also potential confounders in the hypotension-vasopressor relationship.
By Delphi consensus process, 3 variables were identified (hypotension, elevated lactate 
level, and a sustained need for vasopressor therapy) to test in cohort studies, exploring 
alternative combinations and different lactate thresholds. The first database interrogated was 
the Surviving Sepsis Campaign’s international multicenter registry of 28 150 infected 
patients with at least 2 SIRS criteria and at least 1 organ dysfunction criterion. Hypotension 
was defined as a mean arterial pressure less than 65 mm Hg, the only available cutoff. A 
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total of 18 840 patients with vasopressor therapy, hypotension, or hyperlactatemia (>2 
mmol/L [18 mg/dL]) after volume resuscitation were identified. Patients with fluid-resistant 
hypotension requiring vasopressors and with hyperlactatemia were used as the referent 
group for comparing between-group differences in the risk-adjusted odds ratio for mortality. 
Risk adjustment was performed with a generalized estimating equation population-averaged 
logistic regression model with exchangeable correlation structure.
Risk-adjusted hospital mortality was significantly higher (P < .001 compared with the 
referent group) in patients with fluid-resistant hypotension requiring vasopressors and 
hyperlactatemia (42.3% and 49.7% at thresholds for serum lactate level of >2 mmol/L [18 
mg/dL] or >4 mmol/L [36 mg/dL], respectively) compared with either hyperlactatemia alone 
(25.7% and 29.9% mortality for those with serum lactate level of >2 mmol/L [18 mg/dL] 
and >4 mmol/L [36 mg/dL], respectively) or with fluid-resistant hypotension requiring 
vasopressors but with lactate level of 2 mmol/L (18mg/dL) or less (30.1%).
With the same 3 variables and similar categorization, the unadjusted mortality in infected 
patients within 2 unrelated large electronic health record data sets (University of Pittsburgh 
Medical Center [12 hospitals; 2010–2012; n = 5984] and Kaiser Permanente Northern 
California [20 hospitals; 2009–2013; n = 54 135]) showed reproducible results. The 
combination of hypotension, vasopressor use, and lactate level greater than 2 mmol/L (18 
mg/dL) identified patients with mortality rates of 54% at University of Pittsburgh Medical 
Center (n = 315) and 35% at Kaiser Permanente Northern California (n = 8051). These rates 
were higher than the mortality rates of 25.2% (n = 147) and 18.8% (n = 3094) in patients 
with hypotension alone, 17.9% (n = 1978) and 6.8% (n = 30 209) in patients with lactate 
level greater than 2 mmol/L (18 mg/dL) alone, and 20% (n = 5984) and 8% (n = 54 135) in 
patients with sepsis at University of Pittsburgh Medical Center and Kaiser Permanente 
Northern California, respectively.
The task force recognized that serum lactate measurements are commonly, but not 
universally, available, especially in developing countries. Nonetheless, clinical criteria for 
septic shock were developed with hypotension and hyperlactatemia rather than either alone 
because the combination encompasses both cellular dysfunction and cardiovascular 
compromise and is associated with a significantly higher risk-adjusted mortality. This 
proposal was approved by a majority (13/18; 72.2%) of voting members13 but warrants 
revisiting. The Controversies and Limitations section below provides further discussion 
about the inclusion of both parameters and options for when lactate level cannot be 
measured.
Recommendations for ICD Coding and for Lay Definitions
In accordance with the importance of accurately applying diagnostic codes, Table 2 details 
how the new sepsis and septic shock clinical criteria correlate with ICD-9-CM and ICD-10 
codes. The task force also endorsed the recently published lay definition that “sepsis is a 
life-threatening condition that arises when the body’s response to infection injures its own 
tissues,” which is consistent with the newly proposed definitions described above.35 To 
transmit the importance of sepsis to the public at large, the task force emphasizes that sepsis 
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may portend death, especially if not recognized early and treated promptly. Indeed, despite 
advances that include vaccines, antibiotics, and acute care, sepsis remains the primary cause 
of death from infection. Widespread educational campaigns are recommended to better 
inform the public about this lethal condition.
Controversies and Limitations
There are inherent challenges in defining sepsis and septic shock. First and foremost, sepsis 
is a broad term applied to an incompletely understood process. There are, as yet, no simple 
and unambiguous clinical criteria or biological, imaging, or laboratory features that uniquely 
identify a septic patient. The task force recognized the impossibility of trying to achieve 
total consensus on all points. Pragmatic compromises were necessary, so emphasis was 
placed on generalizability and the use of readily measurable identifiers that could best 
capture the current conceptualization of underlying mechanisms. The detailed, data-guided 
deliberations of the task force during an 18-month period and the peer review provided by 
bodies approached for endorsement highlighted multiple areas for discussion. It is useful to 
identify these issues and provide justifications for the final positions adopted.
The new definition of sepsis reflects an up-to-date view of pathobiology, particularly in 
regard to what distinguishes sepsis from uncomplicated infection. The task force also offers 
easily measurable clinical criteria that capture the essence of sepsis yet can be translated and 
recorded objectively (Figure). Although these criteria cannot be all-encompassing, they are 
simple to use and offer consistency of terminology to clinical practitioners, researchers, 
administrators, and funders. The physiologic and biochemical tests required to score SOFA 
are often included in routine patient care, and scoring can be performed retrospectively.
The initial, retrospective analysis indicated that qSOFA could be a useful clinical tool, 
especially to physicians and other practitioners working outside the ICU (and perhaps even 
outside the hospital, given that qSOFA relies only on clinical examination findings), to 
promptly identify infected patients likely to fare poorly. However, because most of the data 
were extracted from extracted US databases, the task force strongly encourages prospective 
validation in multiple US and non-US health care settings to confirm its robustness and 
potential for incorporation into future iterations of the definitions. This simple bedside score 
may be particularly relevant in resource-poor settings in which laboratory data are not 
readily available, and when the literature about sepsis epidemiology is sparse.
Neither qSOFA nor SOFA is intended to be a stand-alone definition of sepsis. It is crucial, 
however, that failure to meet 2 or more qSOFA or SOFA criteria should not lead to a deferral 
of investigation or treatment of infection or to a delay in any other aspect of care deemed 
necessary by the practitioners. qSOFA can be rapidly scored at the bedside without the need 
for blood tests, and it is hoped that it will facilitate prompt identification of an infection that 
poses a greater threat to life. If appropriate laboratory tests have not already been 
undertaken, this may prompt testing to identify biochemical organ dysfunction. These data 
will primarily aid patient management but will also enable subsequent SOFA scoring. The 
task force wishes to stress that SIRS criteria may still remain useful for the identification of 
infection.
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Some have argued that lactate measurement should be mandated as an important 
biochemical identifier of sepsis in an infected patient. Because lactate measurement offered 
no meaningful change in the predictive validity beyond 2 or more qSOFA criteria in the 
identification of patients likely to be septic, the task force could not justify the added 
complexity and cost of lactate measurement alongside these simple bedside criteria. The task 
force recommendations should not, however, constrain the monitoring of lactate as a guide 
to therapeutic response or as an indicator of illness severity.
Our approach to hyperlactatemia within the clinical criteria for septic shock also generated 
conflicting views. Some task force members suggested that elevated lactate levels represent 
an important marker of “cryptic shock” in the absence of hypotension. Others voiced 
concern about its specificity and that the nonavailability of lactate measurement in resource-
poor settings would preclude a diagnosis of septic shock. No solution can satisfy all 
concerns. Lactate level is a sensitive, albeit nonspecific, stand-alone indicator of cellular or 
metabolic stress rather than “shock.”32 However, the combination of hyperlactatemia with 
fluid-resistant hypotension identifies a group with particularly high mortality and thus offers 
a more robust identifier of the physiologic and epidemiologic concept of septic shock than 
either criterion alone. Identification of septic shock as a distinct entity is of epidemiologic 
rather than clinical importance. Although hyperlactatemia and hypotension are clinically 
concerning as separate entities, and although the proposed criteria differ from those of other 
recent consensus statements,34 clinical management should not be affected. The greater 
precision offered by data-driven analysis will improve reporting of both the incidence of 
septic shock and the associated mortality, in which current figures vary 4-fold.3 The criteria 
may also enhance insight into the pathobiology of sepsis and septic shock. In settings in 
which lactate measurement is not available, the use of a working diagnosis of septic shock 
using hypotension and other criteria consistent with tissue hypoperfusion (eg, delayed 
capillary refill36) may be necessary.
The task force focused on adult patients yet recognizes the need to develop similar updated 
definitions for pediatric populations and the use of clinical criteria that take into account 
their age-dependent variation in normal physiologic ranges and in pathophysiologic 
responses.
Implications
The task force has generated new definitions that incorporate an up-to-date understanding of 
sepsis biology, including organ dysfunction (Box 3). However, the lack of a criterion 
standard, similar to its absence in many other syndromic conditions, precludes unambiguous 
validation and instead requires approximate estimations of performance across a variety of 
validity domains, as outlined above. To assist the bedside clinician, and perhaps prompt an 
escalation of care if not already instituted, simple clinical criteria (qSOFA) that identify 
patients with suspected infection who are likely to have poor outcomes, that is, a prolonged 
ICU course and death, have been developed and validated.
This approach has important epidemiologic and investigative implications. The proposed 
criteria should aid diagnostic categorization once initial assessment and immediate 
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management are completed. qSOFA or SOFA may at some point be used as entry criteria for 
clinical trials. There is potential conflict with current organ dysfunction scoring systems, 
early warning scores, ongoing research studies, and pathway developments. Many of these 
scores and pathways have been developed by consensus, whereas an important aspect of the 
current work is the interrogation of data, albeit retrospectively, from large patient 
populations. The task force maintains that standardization of definitions and clinical criteria 
is crucial in ensuring clear communication and a more accurate appreciation of the scale of 
the problem of sepsis. An added challenge is that infection is seldom confirmed 
microbiologically when treatment is started; even when microbiological tests are completed, 
culture-positive “sepsis” is observed in only 30% to 40% of cases. Thus, when sepsis 
epidemiology is assessed and reported, operationalization will necessarily involve proxies 
such as antibiotic commencement or a clinically determined probability of infection. Future 
epidemiology studies should consider reporting the proportion of microbiology-positive 
sepsis.
Greater clarity and consistency will also facilitate research and more accurate coding. 
Changes to ICD coding may take several years to enact, so the recommendations provided in 
Table 2 demonstrate how the new definitions can be applied in the interim within the current 
ICD system.
The debate and discussion that this work will inevitably generate are encouraged. Aspects of 
the new definitions do indeed rely on expert opinion; further understanding of the biology of 
sepsis, the availability of new diagnostic approaches, and enhanced collection of data will 
fuel their continued reevaluation and revision.
Conclusions
These updated definitions and clinical criteria should clarify long-used descriptors and 
facilitate earlier recognition and more timely management of patients with sepsis or at risk 
of developing it. This process, however, remains a work in progress. As is done with 
software and other coding updates, the task force recommends that the new definition be 
designated Sepsis-3, with the 1991 and 2001 iterations being recognized as Sepsis-1 and 
Sepsis-2, respectively, to emphasize the need for future iterations.
Acknowledgments
Dr Singer reports serving on the advisory boards of InflaRx, Bayer, Biotest, and Merck and that his institution has 
received grants from the European Commission, UK National Institute of Health Research, Immunexpress, DSTL, 
and Wellcome Trust. Dr Deutschman reports holding patents on materials not related to this work and receiving 
travel/accommodations and related expenses for participation in meetings paid by the Centers for Disease Control 
and Prevention, World Federation of Societies of Intensive and Critical Care, Pennsylvania Assembly of Critical 
Care Medicine/PA Chapter, Society of Critical Care Medicine (SCCM)/Penn State–Hershey Medical Center, 
Society of Critical Care Medicine, Northern Ireland Society of Critical Care Medicine, International Sepsis Forum, 
Department of Anesthesiology, Stanford University, Acute Dialysis Quality Initiative, and European Society of 
Intensive Care Medicine (ESICM). Dr Seymour reports receiving personal fees from Beckman Coulter and a 
National Institutes of Health (NIH) grant awarded to his institution. Dr Bauer reports support for travel to meetings 
for the study from ESICM, payment for speaking from CSL Behring, grants to his institution from Jena University 
Hospital, and patents held by Jena University Hospital. Dr Bernard reports grants from AstraZeneca for activities 
outside the submitted work. Dr Chiche reports consulting for Nestle and Abbott and honoraria for speaking from 
GE Healthcare and Nestle. Dr Coopersmith reports receiving grants from the NIH for work not related to this 
article. Dr Coopersmith also reports bring president-elect and president of SCCM when the task force was meeting 
Singer et al. Page 13
JAMA. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and the article was being drafted. A stipend was paid to Emory University for his time spent in these roles. Dr 
Hotchkiss reports consulting on sepsis for GlaxoSmithKline, Merck, and Bristol-Meyers Squibb and reports that his 
institution received grant support from Bristol-Meyers Squibb and GlaxoSmithKline, as well as the NIH, for 
research on sepsis. Dr Marshall reports serving on the data and safety monitoring board (DSMB) of AKPA Pharma 
and Spectral Medical Steering Committee and receiving payment for speaking from Toray Ltd and Uni-Labs. Dr 
Martin reports serving on the board for SCCM and Project Help, serving on the DSMB for Cumberland 
Pharmaceuticals and Vanderbilt University, serving on the medical advisory board for Grifols and Pulsion Medical 
Systems, and grants to his institution from NIH, the Food and Drug Administration, Abbott, and Baxter. Dr Opal 
reports grants from GlaxoSmithKline, Atoxbio, Asahi-Kasei, Ferring, Cardeas, and Arsanis outside the submitted 
work; personal fees from Arsanis, Aridis, Bioaegis, Cyon, and Battelle; and serving on the DSMB for Achaogen, 
Spectral Diagnostics, and Paratek.
Funding/Support: This work was supported in part by a grant from the Society of Critical Care Medicine (SCCM) 
and the European Society of Intensive Care Medicine (ESICM).
Role of the Funder/Sponsor: These funding bodies appointed cochairs but otherwise had no role in the design and 
conduct of the work; the collection, management, analysis, and interpretation of the data; preparation of the 
manuscript; or decision to submit the manuscript for publication. As other national and international societies, they 
were asked for comment and endorsement.
Additional Contributions: The task force would like to thank Frank Brunkhorst, MD, University Hospital Jena, 
Germany; Theodore J. Iwashyna, MD, PhD, University of Michigan; Vincent Liu, MD, MSc, Kaiser Permanente 
Northern California; Thomas Rea, MD, MPH, University of Washington; and Gary Phillips, MAS, Ohio State 
University; for their invaluable assistance, and the administrations and leadership of SCCM and ESICM for 
facilitating its work. Payment was provided to the Center for Biostatistics, Ohio State University, to support the 
work of Mr Phillips.
Endorsing Societies
Academy of Medical Royal Colleges (UK); American Association of Critical Care Nurses; 
American Thoracic Society (endorsed August 25, 2015); Australian–New Zealand Intensive 
Care Society (ANZICS); Asia Pacific Association of Critical Care Medicine; Brasilian 
Society of Critical Care; Central American and Caribbean Intensive Therapy Consortium; 
Chinese Society of Critical Care Medicine; Chinese Society of Critical Care Medicine–
China Medical Association; Critical Care Society of South Africa; Emirates Intensive Care 
Society; European Respiratory Society; European Resuscitation Council; European Society 
of Clinical Microbiology and Infectious Diseases and its Study Group of Bloodstream 
Infections and Sepsis; European Society of Emergency Medicine; European Society of 
Intensive Care Medicine; European Society of Paediatric and Neonatal Intensive Care; 
German Sepsis Society; Indian Society of Critical Care Medicine; International Pan Arabian 
Critical Care Medicine Society; Japanese Association for Acute Medicine; Japanese Society 
of Intensive Care Medicine; Pan American/Pan Iberian Congress of Intensive Care; Red 
Intensiva (Sociedad Chilena de Medicina Critica y Urgencias); Sociedad Peruana de 
Medicina Critica; Shock Society; Sociedad Argentina de Terapia Intensiva; Society of 
Critical Care Medicine; Surgical Infection Society; World Federation of Pediatric Intensive 
and Critical Care Societies; World Federation of Critical Care Nurses; World Federation of 
Societies of Intensive and Critical Care Medicine.
REFERENCES
1. Torio, CM.; Andrews, RM. [Accessed October 31, 2015] National inpatient hospital costs: the most 
expensive conditions by payer, 2011. Statistical Brief #160. Healthcare Cost and Utilization Project 
(HCUP) Statistical Briefs. 2013 Aug. http://www.ncbi.nlm.nih.gov/books/NBK169005/
2. Iwashyna TJ, Cooke CR, Wunsch H, Kahn JM. Population burden of long-term survivorship after 
severe sepsis in older Americans. J Am Geriatr Soc. 2012; 60(6):1070–1077. [PubMed: 22642542] 
Singer et al. Page 14
JAMA. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
3. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe 
sepsis in the United States. Crit Care Med. 2013; 41(5):1167–1174. [PubMed: 23442987] 
4. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign Guidelines Committee 
Including the Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for 
management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41(2):580–637. 
[PubMed: 23353941] 
5. Rhee C, Gohil S, Klompas M. Regulatory mandates for sepsis care—reasons for caution. N Engl J 
Med. 2014; 370(18):1673–1676. [PubMed: 24738642] 
6. Vincent J-L, Marshall JC, Namendys-Silva SA, et al. ICON Investigators. Assessment of the 
worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respir 
Med. 2014; 2(5):380–386. [PubMed: 24740011] 
7. Fleischmann C, Scherag A, Adhikari NK, et al. International Forum of Acute Care Trialists. 
Assessment of global incidence and mortality of hospital-treated sepsis: current estimates and 
limitations. Am J Respir Crit Care Med. 2015
8. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional 
disability among survivors of severe sepsis. JAMA. 2010; 304(16):1787–1794. [PubMed: 
20978258] 
9. Bone RC, Balk RA, Cerra FB, et al. American College of Chest Physicians/Society of Critical Care 
Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use 
of innovative therapies in sepsis. Crit Care Med. 1992; 20(6):864–874. [PubMed: 1597042] 
10. Levy MM, Fink MP, Marshall JC, et al. International Sepsis Definitions Conference. 2001 SCCM/
ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003; 
29(4):530–538. [PubMed: 12664219] 
11. Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013; 
381(9868):774–775. [PubMed: 23472921] 
12. Seymour CW, Liu V, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis. JAMA. 
13. Shankar-Hari M, Phillips G, Levy ML, et al. Assessment of definition and clinical criteria for 
septic shock. JAMA. 
14. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013; 369(9):840–851. 
[PubMed: 23984731] 
15. Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T. Host innate immune responses to 
sepsis. Virulence. 2014; 5(1):36–44. [PubMed: 23774844] 
16. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular 
dysfunctions to immunotherapy. Nat Rev Immunol. 2013; 13(12):862–874. [PubMed: 24232462] 
17. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014; 40(4):
463–475. [PubMed: 24745331] 
18. Singer M, De Santis V, Vitale D, Jeffcoate W. Multiorgan failure is an adaptive, endocrine-
mediated, metabolic response to overwhelming systemic inflammation. Lancet. 2004; 364(9433):
545–548. [PubMed: 15302200] 
19. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, 
and multiple organ dysfunction. Crit Care Med. 1999; 27(7):1230–1251. [PubMed: 10446814] 
20. Kwan A, Hubank M, Rashid A, Klein N, Peters MJ. Transcriptional instability during evolving 
sepsis may limit biomarker based risk stratification. PLoS One. 2013; 8(3):e60501. [PubMed: 
23544148] 
21. Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, et al. Sepsis: multiple abnormalities, 
heterogeneous responses, and evolving understanding. Physiol Rev. 2013; 93(3):1247–1288. 
[PubMed: 23899564] 
22. Wong HR, Cvijanovich NZ, Anas N, et al. Developing a clinically feasible personalized medicine 
approach to pediatric septic shock. Am J Respir Crit Care Med. 2015; 191(3):309–315. [PubMed: 
25489881] 
23. Langley RJ, Tsalik EL, van Velkinburgh JC, et al. An integrated clinico-metabolomic model 
improves prediction of death in sepsis. Sci Transl Med. 2013; 5(195):195ra95.
24. Chan JK, Roth J, Oppenheim JJ, et al. Alarmins: awaiting a clinical response. J Clin Invest. 2012; 
122(8):2711–2719. [PubMed: 22850880] 
Singer et al. Page 15
JAMA. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
25. Churpek MM, Zadravecz FJ, Winslow C, Howell MD, Edelson DP. Incidence and prognostic value 
of the systemic inflammatory response syndrome and organ dysfunctions in ward patients. Am J 
Respir Crit Care Med. 2015; 192(8):958–964. [PubMed: 26158402] 
26. Kaukonen K-M, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response 
syndrome criteria in defining severe sepsis. N Engl J Med. 2015; 372(17):1629–1638. [PubMed: 
25776936] 
27. Vincent JL, Moreno R, Takala J, et al. Working Group on Sepsis-Related Problems of the European 
Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to 
describe organ dysfunction/failure. Intensive Care Med. 1996; 22(7):707–710. [PubMed: 8844239] 
28. Vincent JL, de Mendonça A, Cantraine F, et al. Working Group on "Sepsis-Related Problems” of 
the European Society of Intensive Care Medicine. Use of the SOFA score to assess the incidence 
of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit 
Care Med. 1998; 26(11):1793–1800. [PubMed: 9824069] 
29. Rubulotta FM, Ramsay G, Parker MM, Dellinger RP, Levy MM, Poeze M. Surviving Sepsis 
Campaign Steering Committee; European Society of Intensive Care Medicine. Society of Critical 
Care Medicine. An international survey: public awareness and perception of sepsis. Crit Care Med. 
2009; 37(1):167–170. [PubMed: 19123265] 
30. Le Gall J-R, Klar J, Lemeshow S, et al. ICU Scoring Group. The Logistic Organ Dysfunction 
system: a new way to assess organ dysfunction in the intensive care unit. JAMA. 1996; 276(10):
802–810. [PubMed: 8769590] 
31. Shah RU, Henry TD, Rutten-Ramos S, Garberich RF, Tighiouart M, Bairey Merz CN. Increasing 
percutaneous coronary interventions for ST-segment elevation myocardial infarction in the United 
States: progress and opportunity. JACC Cardiovasc Interv. 2015; 8(1 pt B):139–146. [PubMed: 
25616918] 
32. Kraut JA, Madias NE. Lactic acidosis. N Engl J Med. 2014; 371(24):2309–2319. [PubMed: 
25494270] 
33. Casserly B, Phillips GS, Schorr C, et al. Lactate measurements in sepsis-induced tissue 
hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med. 2015; 43(3):
567–573. [PubMed: 25479113] 
34. Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic 
monitoring. Task Force of the European Society of Intensive Care Medicine. Intensive Care Med. 
2014; 40(12):1795–1815. [PubMed: 25392034] 
35. Czura CJ. “Merinoff symposium 2010: sepsis”—speaking with one voice. Mol Med. 2011; 17(1–
2):2–3. [PubMed: 21246163] 
36. Ait-Oufella H, Bige N, Boelle PY, et al. Capillary refill time exploration during septic shock. 
Intensive Care Med. 2014; 40(7):958–964. [PubMed: 24811942] 
Singer et al. Page 16
JAMA. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Box 1. SIRS (Systemic Inflammatory Response Syndrome)
Two or more of:
Temperature >38°C or <36°C
Heart rate >90/min
Respiratory rate >20/min or PaCO2 <32 mm Hg (4.3 kPa) White blood cell 
count >12 000/mm3 or <4000/mm3 or >10% immature bands
From Bone et al.9
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Box 2. Key Concepts of Sepsis
• Sepsis is the primary cause of death from infection, especially if not 
recognized and treated promptly. Its recognition mandates urgent 
attention.
• Sepsis is a syndrome shaped by pathogen factors and host factors (eg, 
sex, race and other genetic determinants, age, comorbidities, 
environment) with characteristics that evolve over time. What 
differentiates sepsis from infection is an aberrant or dysregulated host 
response and the presence of organ dysfunction.
• Sepsis-induced organ dysfunction may be occult; therefore, its presence 
should be considered in any patient presenting with infection. 
Conversely, unrecognized infection may be the cause of new-onset 
organ dysfunction. Any unexplained organ dysfunction should thus 
raise the possibility of underlying infection.
• The clinical and biological phenotype of sepsis can be modified by 
preexisting acute illness, long-standing comorbidities, medication, and 
interventions.
• Specific infections may result in local organ dysfunction without 
generating a dysregulated systemic host response.
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Box 3. New Terms and Definitions
• Sepsis is defined as life-threatening organ dysfunction caused by a 
dysregulated host response to infection.
• Organ dysfunction can be identified as an acute change in total SOFA 
score ≥2 points consequent to the infection.
– The baseline SOFA score can be assumed to be zero in 
patients not known to have preexisting organ 
dysfunction.
– ASOFA score ≥2 reflects an overall mortality risk of 
approximately 10% in a general hospital population 
with suspected infection. Even patients presenting with 
modest dysfunction can deteriorate further, 
emphasizing the seriousness of this condition and the 
need for prompt and appropriate intervention, if not 
already being instituted.
• In lay terms, sepsis is a life-threatening condition that arises when the 
body’s response to an infection injures its own tissues and organs.
• Patients with suspected infection who are likely to have a prolonged 
ICU stay or to die in the hospital can be promptly identified at the 
bedside with qSOFA, ie, alteration in mental status, systolic blood 
pressure ≥100 mm Hg, or respiratory rate ≥22/min.
• Septic shock is a subset of sepsis in which underlying circulatory and 
cellular/metabolic abnormalities are profound enough to substantially 
increase mortality.
• Patients with septic shock can be identified with a clinical construct of 
sepsis with persisting hypotension requiring vasopressors to maintain 
MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L 
(18mg/dL) despite adequate volume resuscitation. With these criteria, 
hospital mortality is in excess of 40%.
Abbreviations: MAP, mean arterial pressure; qSOFA, quick SOFA; SOFA: Sequential 
[Sepsis-related] Organ Failure Assessment.
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Box 4. qSOFA (Quick SOFA) Criteria
Respiratory rate ≥22/min
Altered mentation
Systolic blood pressure ≥100 mm Hg
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Figure. 
Operationalization of Clinical Criteria Identifying Patients With Sepsis and Septic Shock
The baseline Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score should be 
assumed to be zero unless the patient is known to have preexisting (acute or chronic) organ 
dysfunction before the onset of infection. qSOFA indicates quick SOFA; MAP, mean arterial 
pressure.
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Table 2
Terminology and International Classification of Diseases Coding
Current Guidelines
and Terminology Sepsis Septic Shock
1991 and 2001
consensus
terminology9,10
Severe sepsis
Sepsis-induced
hypoperfusion
Septic shock13
2015 Definition Sepsis is
life-threatening organ
dysfunction caused by a
dysregulated host
response to infection
Septic shock is a subset of
sepsis in which underlying
circulatory and
cellular/metabolic
abnormalities are profound
enough to substantially
increase mortality
2015 Clinical
criteria
Suspected or
documented infection
and
an acute increase of ≥2
SOFA points (a proxy
for organ dysfunction)
Sepsisa
and
vasopressor therapy needed to
elevate MAP ≥65 mm Hg
and
lactate >2 mmol/L (18 mg/dL)
despite adequate fluid
resuscitation13
Recommended
primary ICD
codesa
  ICD-9 995.92 785.52
  ICD-10a R65.20 R65.21
Framework for
implementation
for coding and
research
Identify suspected infection by using concomitant orders
for blood cultures and antibiotics (oral or parenteral) in a
specified periodb
Within specified period around suspected infectionc:
1. Identify sepsis by using a clinical criterion for
life-threatening organ dysfunction
2. Assess for shock criteria, using administration of
vasopressors, MAP <65 mm Hg, and lactate >2 mmol/L
(18 mg/dL)d
Abbreviations: ICD, International Classification of Diseases; MAP, mean arterial pressure; SOFA, Sequential [Sepsis-related] Organ Failure 
Assessment.27
a
Included training codes.
bSuspected infection could be defined as the concomitant administration of oral or parenteral antibiotics and sampling of body fluid cultures 
(blood, urine, cerebrospinal fluid, peritoneal, etc). For example, if the culture is obtained, the antibiotic is required to be administered within 72 
hours, whereas if the antibiotic is first, the culture is required within 24 hours.12
cConsiders a period as great as 48 hours before and up to 24 hours after onset of infection, although sensitivity analyses have tested windows as 
short as 3 hours before and 3 hours after onset of infection.12
dWith the specified period around suspected infection, assess for shock criteria, using any vasopressor initiation (eg, dopamine, norepinephrine, 
epinephrine, vasopressin, phenylephrine), any lactate level >2 mmol/L (18mg/dL), and mean arterial pressure <65mmHg. These criteria require 
adequate fluid resuscitation as defined by the Surviving Sepsis Campaign guidelines.4
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